ResultsIQ

ResultsIQ › Latest results › Suraksha Diagnostic Limited

Suraksha Diagnostic Limited Q2 FY26 results press release summary

NSE: SURAKSHA · BSE: 544293

Results press release of 10 Nov 2025, summarised by AI from the filing.

Suraksha Diagnostic H1 FY26 total income rose 17.8% to ₹1,530.72 million, with Q2 FY26 total income up 16.9% to ₹795.80 million.

Key takeaways

  1. Q2 FY26 revenue Total income ₹795.80 million (Q2 FY25: ₹680.67 million, +16.9%), driven primarily by test volumes.
  2. H1 FY26 revenue Total income ₹1,530.72 million (H1 FY25: ₹1,299.15 million, +17.8%).
  3. Margin decline Q2 FY26 EBITDA margin 31.7% (Q2 FY25: 36.7%) and PAT margin 11.2% (Q2 FY25: 15.2%).
  4. Volume growth Total tests rose 29.2% to 2.20 million in Q2 FY26; total patients rose 18.2% to 0.38 million.
  5. Network expansion 11 centres added in H1 FY26; 3 hub and 6 spoke centres to be operational in H2 FY26, taking the year's total to 20.

Original filing on BSE

Suraksha Diagnostic Limited Q1 FY27 results

As filed: Revenue ₹87.7 cr (+20% year on year), EBITDA ₹30.4 cr (+32% year on year), PAT ₹12.9 cr (+43% year on year), EBITDA margin 34.7% (+322 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹81.4 cr (+25% year on year), EBITDA ₹24.4 cr (+28% year on year), PAT ₹6.2 cr (−12% year on year), EBITDA margin 29.9% (+70 bps). Score 56 of 100, In line with trend. EBITDA margin rose 70 bps year on year. Tax rate 38%. Not enough history for a trend yet: scored on growth alone. Profit fell 15% from last quarter. Share price after the results: −16.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹77.7 cr (+29% year on year), EBITDA ₹23.2 cr (+29% year on year), PAT ₹7.2 cr (+21% year on year), EBITDA margin 29.8% (−19 bps). Score 70 of 100, Above trend. EBITDA margin fell 19 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −9.7% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹79.0 cr (+18% year on year), EBITDA ₹24.0 cr (0% year on year), PAT ₹9.0 cr (−10% year on year), EBITDA margin 30.4% (−544 bps). Score 36 of 100, Below trend. EBITDA margin fell 544 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −13.0% in 30 days (Nifty 500: −0.8%).
  • Q1 FY26: Revenue ₹70.0 cr, EBITDA ₹24.0 cr, PAT ₹10.0 cr, EBITDA margin 34.3%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹64.0 cr, EBITDA ₹20.0 cr, PAT ₹8.0 cr, EBITDA margin 31.3%. Not scored. No result for the same quarter last year. Share price after the results: −1.7% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹59.0 cr, EBITDA ₹18.0 cr, PAT ₹6.0 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year.
  • Q2 FY25: Revenue ₹66.0 cr, EBITDA ₹24.0 cr, PAT ₹11.0 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Suraksha Diagnostic Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.